Commonly used disease-modifying antirheumatic drugs in the treatment of inflammatory arthritis: An update on mechanisms of action

Clinical and Experimental Rheumatology

Volumn 16, Issue 5, 1998, Pages 595-604

  Danning, C L ^a   Boumpas, D T ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Cell activation; Cytokine production; DMARDs; Mechanisms; Rheumatoid arthritis; Signal transduction

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN A; GLUCOCORTICOID; GOLD SALT; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

AUTOIMMUNITY; CELL PROLIFERATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EFFECTOR CELL; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHLOROQUINE; CYCLOSPORINE; GLUCOCORTICOIDS; GOLD COMPOUNDS; HUMANS; HYDROXYCHLOROQUINE; METHOTREXATE; SULFASALAZINE;

EID: 0031658404     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. GORONZY JJ, WEYAND CM: Rheumatoid arthritis. A. Epidemiology, pathology, and pathogenesis. In: KLIPPEL JH, WEYAND CM, WORTMANN RL (Eds.): Primer on the Rheumatic Diseases (11th ed.), Arthritis Foundation, Atlanta, 1997: 155-61.
2. CRONSTEIN BN: Molecular therapeutics: Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39: 1951-60.
3. BOLOGNA C, EDNO L, ANAYA JM et al.: Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum 1994; 37: 1770-3.
4. BAGGOTT JE, MORGAN SL, HA TS, ALARCON GS, KOOPMAN WJ, KRUMDIECK CL: Antifolates in rheumatoid arthritis: A hypothetical mechanism of action. Clin Exp Rheumatol 1993; 11(Suppl 8): S101-S105.
5. SHIROKY JB, NEVILLE C, ESDAILE JM et al.: Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993; 36: 795-803.
6. WEINBLATT ME, COBLYN JS, FOX DA et al.: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-22.
7. KREMER JM, PHELPS CT: Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: Update after a mean of 90 months. Arthritis Rheum 1992; 35: 138-45.
8. ANDERSON PA, WEST SG, O'DELL JR, VIA CS, CLAYPOOL RG, KOTZIN BL: Weekly pulse methotrexate in rheumatoid arthritis: Clinical and immunologic effects in a randomized double-blind study. Ann Intern Med 1985; 103: 489-96.
9. OLSEN NJ, TEAL GP, BROOK RH: IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis. Agents Actions 1991; 34: 169-71.
10. ALARCON GS, SCHROHENLOHER RE, BARTOLUCCI AA, WARD JR, WILLIAM HJ, KOOPMAN WJ: Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis: Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor. Arthritis Rheum 1990; 33: 1156-61.
11. SPERLING RI, COBLYN JS, LARKIN JK, BENINCASO AI, AUSTEN KF, WEINBLATT ME: Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum 1990; 33: 1149-55.
12. LEROUX JL, DAMON M, CHAVIS C, CRASTES DE PAULET A, BLUTMAN F: Effects of a single dose of methotrexate on 5-and 12-lipoxygenase products in patients with rheumatoid arthritis. J Rheumatol 1992; 19: 863-6.
13. HAWKES JS, CLELAND LG, PROUDMAN SM, JAMES MJ: The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis. J Rheumatol 1994; 21: 55-8.
14. KREMER JM, LAWRENCE DA, JUBIZ W et al.: Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum 1990; 33: 810-20.
15. LAURINDO IMM, MELLO SBV, COSSERMELLI W: Influence of low doses of methotrexate on superoxide anion production by polymorphonuclear leukocytes from patients with rheumatoid arthritis. J Rheumatol 1995; 22: 633-8.
16. WEINBLATT ME, TRENTHAM DE, FRASER PA et al.: Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31: 167-75.
17. KREMER JM: Lymphocyte subset analysis after long-term methotrexate therapy for rheumatoid arthritis (abstract). Arthritis Rheum 1986; 29: S75.
18. JOHNSTON CA, RUSSELL AS, KOVITHAVONGS J, DASGUPTA M: Measures of immunologic and inflammatory responses in vitro in rheumatoid arthritis patients treated with methotrexate. J Rheumatol 1986; 13: 294-6.
19. WASCHER TC, HERMAN J, BREZINSCHEK HP et al.: Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis. Clin Investig 1994; 72: 535-40.
20. SEGAL R, MOZES E, YARON M, TARTAKOVSKY B: The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 1989; 32: 370-7.
21. CHANG DM, BAPTISTE P, SCHUR PH: The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes. J Rheumatol 1990; 17: 1148-57.
22. MEYER FA, YARON I, MASHIAH V, YARON M: Methotrexate inhibits proliferation but not interleukin 1 stimulated secretory activities of cultured human synovial fibroblasts. J Rheumatol 1993; 20: 238-42.
23. CHANG DM, WEINBLATT ME, SCHUR PH: The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. J Rheumatol 1992; 19: 1678-82.
24. KREMER JM, LAWRENCE DH: Correlation of immune parameters with clinical and laboratory effects in a prospective cohort of patients with rheumatoid arthritis receiving methotrexate(abstract). Arthritis Rheum 1992; 35: S144.
25. THOMAS R, CARROLL GJ: Reduction of leukocyte and interleukin-1 beta concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1993; 36: 1244-52.
26. SEITZ M, LOETSCHER P, DEWALD B et al.: Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheum 1995; 34: 602-9.
27. BARRERA P, BOERBOOMS AM, DEMACKER PN, VAN DE PUTTE LB, GALLATI H, VAN DER MEER JW: Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: Effects of a single dose methotrexate. Br J Rheumatol 1994; 33: 1017-24.
28. SMITH-OLIVER T, NOEL LS, STIMPSON SS, YARNALL DP, CONNOLLY KM: Elevated levels of TNF in the joints of adjuvant arthritis rats. Cytokine 1993; 5: 298-304.
29. KREMER JM, PETRILLO GF, LAWRENCE DH: Methotrexate induces significant changes in IL-1, IL-2, IL-6, and IL-8 but not lymphocyte markers in patients with rheumatoid arthritis (abstract). Arthritis Rheum 1993; 36: S77.
30. BARRERA P, BOERBOOMS AM, JANSSEN EM et al.: Circulating tumour necrosis factor receptors, interleukin-2 receptors, tumour necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis: Longitudinal evaluation during methotrexate and azathioprine treatment. Arthritis Rheum 1993; 36: 1070-9.
31. CRILLY A, MCINNES IB, MCDONALD AG, WATSON J, CAPELL HA, MADHOK R: Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate. J Rheumatol 1995; 22: 224-6.
32. CONSTANTIN A, LOUBET-LESCOULIE P, LAMBERT N et al.: Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: Evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum 1998; 41: 48-57.
33. FIRESTEIN GS, PAINE MM, BOYLE DL: Mechanisms of methotrexate action in rheumatoid arthritis: Selective decrease in synovial collagenase gene expression. Arthritis Rheum 1994; 37: 193-200.
34. KREMER JM, LAWRENCE DH: Correlation of immune parameters with clinical response to methotrexate in patients with rheumatoid arthritis: A prospective study (abstract). Arthritis Rheum 1991; 34: S159.
35. KREMER JM: The mechanism of action of methotrexate in rheumatoid arthritis: The search continues. J Rheumatol 1994; 21: 1-5.
36. MARTINEZ-OSUNA P, ZWOLINSKA JB, SIKES DH et al.: Lack of immunosuppressive effect of low-dose oral methotrexate on lymphocytes in rheumatoid arthritis. Clin Exp Rheumatol 1993; 11: 249-53.
37. CRONSTEIN BN, NAIME D, OSTAD E: The anti-inflammatory mechanism of methotrexate: Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92: 2675-82.
38. CRONSTEIN BN, EBERLE MA, GRUBER HE, LEVIN RI: Methotexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 1991; 88: 2441-5.
39. BAGGOTT JE, VAUGHN WH, HUDSON BB: Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986; 236: 193-200.
40. MORABITO L, MONTESINOS MC, SCHREIBMAN DM et al.: Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998; 101: 295-300.
41. CRONSTEIN BN, ROSENSTEIN ED, KRAMER SB, WEISSMANN G, HIRSHHORN R: Adenosine, a physiologic modulator of superoxide anion generation by human neutrophils: Adenosine acts via an A2 receptor on human neutrophils. J Immunol 1985: 135: 1366-71.
42. CRONSTEIN BN, LEVIN RI, PHILIPS MR, HIRSCHHORN R, ABRAMSON SB, WEISSMANN G: Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol 1992; 148: 2201-6.
43. KRUMP E, LEMAY G, BORGEAT P: Adenosine A2 receptor-induced inhibition of leukotriene B4 synthesis in whole blood ex vivo. Br J Pharmacol 1996; 117: 1639-44.
44. DONG RP, KAMEOKA J, HEGEN M et al.: Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 1996; 156: 1349-55.
45. KAMMER GM, BIRCH RE, POLMAR SH: Impaired immunoregulation in systemic lupus erythematosis: Defective adenosine-induced suppressor T lymphocyte generation. J Immunol 1983; 130: 1706-12.
46. SAJJADI FG, TAKABAYASHIK, FOSTER AC, DOMINGO RC, FIRESTEIN GS: Inhibition of TNF-alpha expression by adenosine: Role of A3 adenosine receptors. J Immunol 1996; 156: 3435-42.
47. BOUMA MG, STAD RK, VAN DEN WILDENBERG FA, BUURMAN WA: Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immnuol 1994; 153: 4159-68.
48. BOYLE DL, SAJJADI FG, FIRESTEIN GS: Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthritis Rheum 1996; 39: 923-30.
49. HIRATA S, MATSUBARA T, SAURA R, TATEISHI H, HIROHATA K: Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989; 32: 1065-73.
50. SMEDEGARD G, BJORK J: Sulfasalazine: Mechanism of action in rheumatoid arthritis. Br J Rheumatol 1995; 34 (Suppl. 2): 7-15.
51. FARR A, BRODRICK A, BACON PA: Plasma, synovial fluid concentration of sulphasalazine and two of its metabolites in rheumatoid arthritis. Rheumatol Int 1985; 5: 247-51.
52. SANDBERG-GERTZEN H, KJELLANDER J, SUNDBERG-GILLA B, JARNEROT G: In vitro effects of sulphasalazine, azodisal sodium and their metabolites on Clostridim difficile and some other faecal bacteria. Scand J Gastroenterol 1985; 20: 607-12.
53. BRADLEY SM, NEUMANN VC, BARR K et al.: Sequential study of bacterial antibody levels and faecal flora in rheumatod arthritis patients taking sulphasalazine. Br J Rheumatol 1993; 32: 683-88.
54. SELHUB J, DHAR GJ, ROSENBERG IH: Inhibition of folate enzymes by sulfasalazine. J Clin Invest 1978; 61: 221-4.
55. IMAI F, SUZUKI T, ISHIBASHI T, DOHI Y: Effect of sulfasalazine on B cells. Clin Exp Rheumatol 1991; 9: 259-64.
56. COMER SS, JASIN HE: In vitro immunomodulatory effects of sulfasalazine and its metabolites. J Rheumatol 1988; 15: 580-6.
57. FUJIWARA M, MITSUI K, ISHIDA J, YAMAMOTO I: The effect of salazosulfapyridine on the in vitro antibody production in murine spleen cells. Immunopharmacology 1990; 19: 15-21.
58. GIBSON PR, JEWELL DP: Sulphasalazine and derivatives, natural killer activitiy and ulcerative colitis. Clin Sci 1985; 69: 177-84.
59. HARVATH L. YANCEY KB, KATZ SI: Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones. J Immunol 1986; 137: 1305-11.
60. KLESSEN C: Inhibition of neutral proteases from polymorphonuclear (PMN) neutrophils by salicylazosulfapyridine (SASP). Histochemistry 1980; 66: 43-7.
61. CARLIN G, NYMAN A-K, GRONBERG A: Effects of sulfasalazine on cytokine production by mitogen-stimulated human T-cells (abstract). Arthritis Rheum 1994; 37: S383.
62. GRONBERG A, ISAKSSON P, SMEDEGARD G: Inhibitory effect of sulfasalazine on production of IL-1β, IL-6, and TNFα (abstract). Arthritis Rheum 1994; 37: S383.
63. FUJIWARA M, MITSUI K, YAMAMOTO I: Inhibition of proliferative responses and interleukin 2 production by salazosulfapyridine and its metabolites. Jpn J Immunopharmacol 1990; 54: 121-31.
64. AONO H, HASUNUMA T, FUJISAWA K et al.: Direct suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine. J Rheumatol 1995; 22: 65-70.
65. WAHL C, LIPTAY S, ADLER G, SCHMID RM: Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 22: 65-70.
66. CARLIN G, DJURSATER R, SMEDEGARD G: Inhibitory effects of sulfasalazine and related compounds on superoxide production by human polymorphonuclear leukocytes. Pharmacol Toxicol 1989; 65: 121-7.
67. GADANGI P, LONGAKER M, NAIME D et al.: The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 1996; 156: 1937.
68. SHARON P, DRAB EA, LINDER JS, WEIDMAN SW, SABESIN SM, RUBIN DB: The effect of sulfasalazine on bovine endothelial cell proliferation and cycle phase distribution. Comparison with olsalazine, 5-aminosalicylic acid, and sulfapyridine. J Lab Clin Med 1992; 119: 99-107.
69. MADHOK R, WIJELATH E, SMITH J, WATSON J, STURROCK RD, CAPELL H: Is the beneficial effect of sulfasalazine due to inhibition of synovial neovascularization? J Rheumatol 1991; 18: 199-202.
70. HANDSCHUMACHER RE, HARDING MW, RICE J, DRUGGE RJ, SPEICHER DW: Cyclophilin: A specific cytosolic binding protein for cyclosporin A. Science 1984; 226: 544-6.
71. SCHREIBER SL: Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991; 251: 283.
72. FRUMAN DA, KLEE CB, BIERER BE, BURAKOFF SJ: Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A. Proc Natl Acad Sci USA 1992; 89: 3686-90.
73. FLANAGAN WM, CORTHESY B, BRAM RJ, CRABTREE GR: Nuclear association of a T-cell transcription factor blocked by FK506 and cyclosporin A. Nature 1991; 352: 803-7.
74. EMMEL EA, VERWEIJ CL, DURAND DB, HIGGINS KM, LACY E, CRABTREE GR: Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 1989; 246: 1617-20.
75. O'KEEFE SJ, TAMURA J, KINCAID RL, TOCCI MJ, O'NEILL EA: FK506 and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992; 357: 692-4.
76. REEM GH, COOK LA, VILCEK J: Gamma interferon synthesis by human thymocytes and T lymphocytes inhibited by cyclosporin A. Science 1998; 221: 63-5.
77. GRANELLI-PIPERNO A, ANDRUS L, STEINMAN RM: Lymphokine and non-lymphokine mRNA levels in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A. J Exp Med 1986; 163: 922-37.
78. AHUJA SS, SHRIVASTAV S, DANIELPOUR D, BALOW JE, BOUMPAS DT: Regulation of transforming growth factor-beta 1 and its receptor by cyclosporin in human T lymphocytes. Transplantation 1995; 60: 718-23.
79. FURUE M, KATZ SI: Cyclosporine A inhibits accessory cell and antigen-presenting cell functions of epidermal langerhans cells. Transplant Proc 1988; 20: 87-91.
80. KUROKAWA T, NONAMI T, KOBAYASHI H et al.: Inhibition by cyclosporine of the production of superoxide radicals (letter). N Eng J Med 1992; 326: 840.
81. WERSHIL BK, FURUTA GT, LAVIGNES JA, CHOUDHURY AR, WANG ZS, GALLI SJ: Dexamethasone or cyclosporin A suppress mast cell leukocyte cytokine cascades. Multiple mechanisms of inhibition of IgE and mast cell-dependent cutaneous inflammation in the mouse. J Immunol 1995; 154: 1391.
82. DAWSON J, HURTENBACH U, MACKENZIE A: Cyclosporin A inhibits the in vivo production of interleukin-1β and tumour necrosis factor α, but not interleukin-6, by a T-cell-independent mechanism. Cytokine 1996; 8: 882-8.
83. SIGAL NH, DUMONT FJ: Cyclosporin A, FK-506, and rapamycin: Pharmacologic probes of lymphocyte signal transduction. Ann Rev lmmunol 1992; 10: 519-60.
84. ORCEL P, DENNE MA, DE VERNEJOUL MC: Cyclosporin A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage. Endocrinology 1992: 128: 1638-46.
85. STEWART PJ, GREEN OC, STERN PH: Cyclosporin A inhibits calcemic hormone-induced bone resorption in vitro. J Bone Min Res 1986; 1: 285-91.
86. EPSTEIN S: Cyclosporin A: Friend or foe ? Calcif Tissue Int 1991; 49: 232-4.
87. MEYER S, KOHLER GN, JOLY A: Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kB activation. FEBS Letters 1997; 413: 354-8.
88. HOLSCHERMANN H, DURFELD F, MAUS U et al.: Cyclosporine A inhibits tissue factor expression in monocytes/macrophages. Blood 1996; 88: 3837-45.
89. WICKER LS, BOLTZ JR RC, MATT V, NICHOLS EA, PETERSON LB, SIGAL JH: Suppression of B cell activation by cyclosporin A, FK506, and rapamycin. Ear J Immunol 1990; 20: 2277.
90. ANDJELIC S, KHANNA A, SUTHANTHIRAN M, NIKOLIC-ZUGIC J: Intracellular Ca2+ elevation and cyclosporin A synergistically induce TGF-β1-mediated apoptosis in lymphocytes. J Immunol 1997; 158: 2527-34.
91. WALY DT, DIMARTINO MJ, GRISWOLD DE: Comparative pharmacology and biological effects of different gold compounds. J Rheumatol 1982; 9 (suppl 8): 54-60.
92. REMVIG L, ENK C, BLIGAARD N: Effect of auranofin and sodium aurothiomalate on interleukin-1 production from human monocytes in vivo. Scand J Rheumatol 1988; 17: 255-62.
93. KIRKHAM BW, NAVARRO FJ, CORKILL MM, PANAYI GS: In vivo analysis of disease modifying drug therapy activity in rheumatoid arthritis by sequential immunohistological analysis of synovial membrane interleukin 1 beta. J Rheumatol 1994; 21: 1615-9.
94. MATSUBARA T, SAEGUSA Y, HIROHATA K: Low-dose gold compounds inhibit fibroblast proliferation and do not affect interleukin-1 secretion by macrophages. Arthritis Rheum 1988; 31: 1272-80.
95. CRILLY A, MADHOK R, WATSON J, CAPELL HA, STURROCK RD: Production of interleukin-6 by monocytes isolated from rheumatoid arthritis patients receiving second line drug therapy. Br J Rheumatol 1994; 33: 822-5.
96. EVANS GF, ZUCKERMAN SH: Pharmacologic modulation of tumor necrosis factor production by endotoxin stimulated macrophages: In vitro and in vivo effects of auranofin and other chrysotherapeutic compounds. Agents Actions 1989; 26: 329-34.
97. LOETSCHER P, DEWALD B, BAGGIOLINI M, SEITZ M: Monocyte chemoattractant protein 1 and interleukin-8 production by rheumatoid synoviocytes: Effects of anti-rheumatic drugs. Cytokine 1994; 6: 162-70.
98. SEITZ M, DEWALD B, CESKS M, GERBER N, BAGGIOLINI M: Interleukin-8 in inflammatory rheumatic diseases: Synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate. Rheumatol Int 1992; 12: 159-64.
99. SFIKAKIS PP, SOULIOTIS VL, PANAYIOTIDIS PP: Suppression of interleukin-2 and interleukin-2 receptor biosynthesis by gold compounds in in vitro activated human peripheral blood mononuclear cells. Arthritis Rheum 1993; 36: 208-12.
100. NEWMAN PM, TO SST, ROBINSON BG, HYLAND VJ SCHREIBER L: Effect of gold sodium thiomalate and its thiomalate component on the in vitro expression of endothelial cell adhesion molecules. J Clin Invest 1994; 94: 1864-71.
101. COLUMBO M, GALEONE D, GUIDI G et al.: Modulation of mediator release from human basophils and pulmonary mast cells and macrophages by auranofin. Biochem Pharmcol 1990; 39: 285-91.
102. ANDERSON R, VAN RENSBURG CEJ, JOONE GK, LESSING A: Auranofin inactivates phosphofructokinase in human neutrophils, leading to depletion of intracellular ATP and inhibition of superoxide generation and locomotion. Mol Pharmacol 1994; 40: 427-34.
103. DAVIS P, JOHNSTON C, MILLER CL, WONG K: Effects of gold compounds on the function of phagocytic cells II. Arthritis Rheum 1983; 26: 82-6.
104. ELMGREEN J, AHNFELT-RONNE J, NIELSEN OH: Inhibition of arachidonate via the 5-lipoxygenase pathway. Ann Rheum Dis 1989; 48: 134-8.
105. GRIEM P, TAKAHASHI K, KALBACHER H, GLEICHMANN E: The anti-rheumatic drug disodium aurothiomalate inhibits CD4 positive T cell recognition of peptides containing two or more cystein residues. J Immunol 1995; 155: 1575-87.
106. LEWIS AJ, CARLSON RP, CHANG J, DELUSTRO P: Effect of gold salts, D-penicillamine and benoxaprofen on type II collagen-induced arthritis in rats. Agents Action 1984; 14: 707-14.
107. PETERS-GOLDEN M, SHELLY C: The oral gold compound auranofin triggers arachidonate release and cyclooxygenase metabolism in the alveolar macrophage. Prostaglandins 1989; 36: 773-86.
108. YAMADA M, NIKI H, YAMASHITA M, MUE S, OHUCHI K: Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages. J Pharm Exp Ther 1997; 281: 1005-12.
109. HASHIMOTO K, WHITEHURST CE, MATSUBARA T, HIROHATA K, LIPSKY PE: Immunomodulator effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase C. J Clin Invest 1992; 89: 1839-48.
110. HASHIMOTO K, WHITEHURST CE, LIPSKY PE: Synergistic inhibition of T cell proliferation by gold sodium thiomalate and auranofin. J Rheumatol 1994; 21: 1020-6.
111. YANG J-P, MERIN JP, NAKANO T, KATO T, KITADE Y, OKAMOTO T: Inhibition of the DNA-binding activity of NF-kB by gold compounds in vitro. FEBSLetters 1995; 361: 89-96.
112. HANDEL ML, WATTS CKW, DEFAZIO A, DAY RO, SUTHERLAND RI: Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos. Proc Natl Acad Sci USA 1995; 92: 4497-501.
113. FRENCH JK, HURST NP, O'DONNELL ML, BETTS WH: Uptake of chloroquine and hydroxychloroquine by human blood leukocytes in vitro: Relation to cellular concentrations during antirheumatic therapy. Ann Rheum Dis 1987; 46: 42-5.
114. MACINTYRE AC, CUTHER DJ: Role of lysosomes in hepatic accumulation of chloroquine. J Rheumatol 1988; 77: 196-9.
115. GONZALES-NORIEGA A, GRUBB JH, TALKAD V, SLY WS: Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling. J Cell Biol 1980; 85: 839-52.
116. SALMERON G, LIPSKY PE: Immunosuppressive potential of antimalarials. Am J Med 1983; 75: 19-24.
117. PICOT S, PEYRON F, VUILLEZ JP, POLACK B, AMBROISE-THOMAS P: Chloroquine inhibits tumor necrosis factor production by human macrophages in vitro (letter). J Infect Dis 1991; 164: 830.
118. LARDEWE RB, MILTENBURG AM, BREEDVELD FC, DAHA MR, DIJKMANS BA. Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis. J Rheumatol 1992; 19: 1353-7.
119. SPERBER K, QURAISHI H, KALB TH, PANJA A, STECHER V, MAYER L: Selective regulation of cytokine secretion by hydoxychloroquine: Inhibition of interleukin-1 alpha (IL-1 alpha) and IL-6 in human monocytes and T cells. J Rheumatol 1993; 20: 803-8.
120. HURST NP, FRENCH JK, GORJATSCHKO L: Chloroquine and hydroxychloroquine inhibit multiple sites in metabolic pathways leading to neutrophil superoxide release. J Rheumatol 1988; 15: 23-7.
121. GREY HM, CHESNUT R: Antigen processing and presentation to T cells. Immunol Today 1985; 6: 101-10.
122. GUIDOS C, WONG M, LEE KC: A comparison of the stimulatory activities of lymphoid dendritic cells and macrophages in T cells proliferative to various antigens. J Immunol 1984; 133: 1179-85.
123. BONDESON J: The mechanisms of action of disease-modifying antirheumatic drugs: A review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Gen Pharmacol 1997; 29: 127-50.
124. MENG XW, FELLER JM, ZIEGLER JB, PITTMAN SM, IRELAND CM: Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine. Arthritis Rheum 1997; 40: 927-35.
125. BOUMPAS DT, CHROUSOS GP, WILDER RL, CUPPS TR, BALOW JE: Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates. Ann Intern Med 1993; 119: 1198-208.
126. KERN JA, LAUMB RJ, REED JC, DANIELE RP, NOWELL PC: Dexamethasone inhibition of interleukin-1β production by human monocytes. Post-transcriptional mechanisms. J Clin Invest 1988; 81: 237-44.
127. FESSLER BJ, PALIOGIANNI F, HAMA N, BALOW JE, BOUMPAS DT: Glucocorticoids modulate CD28 mediated pathways for interleukin-2 production in human T cells. Evidence for post-trascriptional regulation. Transplantation 1996; 62: 1113-8.
128. PALIOGIANNI F, AHUJA SS, BALOW JP, BALOW JE, BOUMPAS DT: Novel mechanism for inhibition of human T cells by glucocorticoids: Glucocortocoids inhibit signal transduction through interleukin-2 receptor. J Immunol 1993; 151: 4081-9.
129. SCHEINMAN RI, COGSWELL PC, LOFQUIST AK, BALDWIN JR AS: Role of transcription activation of IkBα in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-6.
130. AUPHAN N, DIDONATO JA, ROSETTE C, HELMBERG A, KARIN M: Immunosuppression by glucocorticoids: Inhibition of NF-kB activity through induction of IkB synthesis. Science 1995; 270: 286-90.
131. CAMPION GV, LEBSACK ME, LOOKABAUGH Y, GORDON G, CATALANE M, and the IL-1RA ARTHRITIS STUDY GROUP: Dose-range and dose-frequency study of human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1092-101.
132. ELLIOT MJ, MAINI RN, FELDMAN M et al.: Randomized double-blind comparison of chimeric monoclonal antibody to TNF (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
133. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with recombinant human TNF receptor (p75)-Fc fusion protein. N Eng J Med 1997; 337: 141-7.
134. MAINI RN, PAULUS H, BREEDVELD FC et al.: rHUIL-10 in subjects with active rheumatoid arthritis (RA). A Phase I and cytokine response study (abstract). Arthritis Rheum 1997; 40 (Suppl. 9): S224.
135. KATSIKIS PD, CHU C-Q, BRENNAN FM, MAINI RN, FELDMAN M: Immunoregulatory role of interleukin-10 in rheumatoid arthritis. J Exp Med 1994; 179: 1517-27.
136. TASSIULAS IO, BOUMPAS DT, FLEISHER TA et al.: A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy (abstract). J Am Soc Nephrol 1996; 7: 1782.
137. DAVIS, JR JC, AUSTIN HA, BOUMPAS DT et al.: A pilot study of 2-chloro-2-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum 1998; 41: 335-43.
138. DAVIS Jr JC, FESSLER BJ, TASSIULAS IO et al.: High-dose versus low-dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis. J Rheumatol 1998 (in press).
139. TASSIULAS IO, DAVIS Jr JC, FESSLER BJ et al.: Fludarabine in non-malignant disorders. In CHESON BD, KEATING MJ, PLUNKET W (Eds.): Nucleoside Analogs in Cancer Therapy, NY, Marcel Decker Inc., 1997: 383-414.